Home › Compare › AGPYY vs ABBV
AGPYY yields 124.22% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 8
Combined, AGPYY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AGPYY + ABBV for your $10,000?
Agile Group Holdings Limited, an investment holding company, engages in the property development, property management, hotel operation, property investment, environmental protection, and other businesses in the People's Republic of China. As of December 31, 2021, the company had a land bank with a total gross floor area of 47.37 million square meters in 84 cities located in Southern China region, Eastern China region, Western China region, Central China region, Hainan and Yunnan region, Northeast China region, Northern China region, Hong Kong, and internationally. It also provides property management services, as well as residential property management, asset management, public property management, civil services, and community business. In addition, the company provides operation of ecological industrial park, hazardous waste treatment, and daily waste treatment to commercial food waste treatment; and sludge treatment, soil treatment, and water restoration to sewage treatment, and water affairs. The company was formerly known as Agile Property Holdings Limited and changed its name to Agile Group Holdings Limited in July 2016. The company was incorporated in 2005 and is headquartered in Guangzhou, the People's Republic of China. Agile Group Holdings Limited is a subsidiary of Top Coast Investment Limited.
Full AGPYY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.